Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Choudhury

Showing results (121-130 of 160) with videos related to

Pageof 16
Sort By:
JCO Precision Oncology|September 14, 2022
Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate CancerJacob E Berchuck, Daniel Boiarsky, Rebecca Silver, et al.
Cancer|November 20, 2020
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignanciesBradley Alexander McGregor, Matthew T Campbell, Wanling Xie, et al.
Cancer Research|December 1, 2016
Castration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6Atish D Choudhury, Anna C Schinzel, Maura B Cotter, et al.
JCI Insight|August 9, 2022
Patterns of structural variation define prostate cancer across disease statesMeng Zhou, Minjeong Ko, Anna Ch Hoge, et al.
Cureus|March 2, 2023
Understanding the Demographic, Clinical, and Real-Time Polymerase Chain Reaction Profiles of COVID-19 Patients in a Tertiary Care Hospital in Northeast IndiaBornali S Dutta, Kalyan Nath, Manash J Taw, et al.
European Urology Oncology|November 15, 2024
Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate CancerPraful Ravi, Caiwei Zhong, Wanling Xie, et al.
The Prostate|March 19, 2025
Outcome of Subsequent Therapies After <sup>177</sup>Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center ExperienceMeryam Losee, Michael Kavanaugh, Mofei Liu, et al.
Integrative Biology : Quantitative Biosciences From Nano to Macro|February 14, 2014
Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traitsXiaosai Yao, Atish D Choudhury, Yvonne J Yamanaka, et al.
Cancer|January 1, 2024
Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trialRana R McKay, Wanling Xie, Xiaoyu Yang, et al.
NPJ Precision Oncology|April 28, 2026
Multi-modal circulating cell-free DNA profiling to predict response to docetaxel in metastatic castration-resistant prostate cancerDavid D Chen, Anat Zimmer, David D Yang, et al.
Pageof 16

Showing results (121-130 of 160) with videos related to

Sort By:
Pageof 16
JCO Precision Oncology|September 14, 2022
Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate CancerJacob E Berchuck, Daniel Boiarsky, Rebecca Silver, et al.
Cancer|November 20, 2020
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignanciesBradley Alexander McGregor, Matthew T Campbell, Wanling Xie, et al.
Cancer Research|December 1, 2016
Castration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6Atish D Choudhury, Anna C Schinzel, Maura B Cotter, et al.
JCI Insight|August 9, 2022
Patterns of structural variation define prostate cancer across disease statesMeng Zhou, Minjeong Ko, Anna Ch Hoge, et al.
Cureus|March 2, 2023
Understanding the Demographic, Clinical, and Real-Time Polymerase Chain Reaction Profiles of COVID-19 Patients in a Tertiary Care Hospital in Northeast IndiaBornali S Dutta, Kalyan Nath, Manash J Taw, et al.
European Urology Oncology|November 15, 2024
Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate CancerPraful Ravi, Caiwei Zhong, Wanling Xie, et al.
The Prostate|March 19, 2025
Outcome of Subsequent Therapies After <sup>177</sup>Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center ExperienceMeryam Losee, Michael Kavanaugh, Mofei Liu, et al.
Integrative Biology : Quantitative Biosciences From Nano to Macro|February 14, 2014
Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traitsXiaosai Yao, Atish D Choudhury, Yvonne J Yamanaka, et al.
Cancer|January 1, 2024
Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trialRana R McKay, Wanling Xie, Xiaoyu Yang, et al.
NPJ Precision Oncology|April 28, 2026
Multi-modal circulating cell-free DNA profiling to predict response to docetaxel in metastatic castration-resistant prostate cancerDavid D Chen, Anat Zimmer, David D Yang, et al.
Pageof 16